Last reviewed · How we verify
Placebo to match zanamivir
Placebo to match zanamivir is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Control arm in zanamivir clinical trials (influenza).
This is an inert placebo formulation designed to match the physical and sensory characteristics of zanamivir for blinded clinical trial comparisons.
This is an inert placebo formulation designed to match the physical and sensory characteristics of zanamivir for blinded clinical trial comparisons. Used for Control arm in zanamivir clinical trials (influenza).
At a glance
| Generic name | Placebo to match zanamivir |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Placebos are inactive substances used in controlled trials to establish the true efficacy of an active drug by comparison. This particular placebo is formulated to mimic zanamivir (an inhaled antiviral), likely matching its appearance, taste, and administration method to maintain blinding in phase 3 trials. It contains no active pharmaceutical ingredient and produces no therapeutic effect.
Approved indications
- Control arm in zanamivir clinical trials (influenza)
Common side effects
Key clinical trials
- Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza (PHASE3)
- A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match zanamivir CI brief — competitive landscape report
- Placebo to match zanamivir updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Placebo to match zanamivir
What is Placebo to match zanamivir?
How does Placebo to match zanamivir work?
What is Placebo to match zanamivir used for?
Who makes Placebo to match zanamivir?
What development phase is Placebo to match zanamivir in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Control arm in zanamivir clinical trials (influenza)
- Compare: Placebo to match zanamivir vs similar drugs
- Pricing: Placebo to match zanamivir cost, discount & access